Ranpak unveils in-line printing for packaging automation
Ranpak Holdings has launched Print'it!, an in-line printing solution designed for automated packaging lines.
This new offering enables full-colour custom printing on up to 15 boxes per minute, catering to various box heights.
Print'it! is set to provide customers with the ability to personalise packaging on-demand, streamlining the branding process within their existing automation systems.
The company noted that its new solution is suitable for businesses that manage multiple brands or seek to create a more personal connection with their customers through customised messages.
By integrating Print'it! into standardised automated packaging lines, companies can eliminate the need for maintaining a stock of preprinted boxes, thereby reducing the complexity of inventory management, the company added.
When paired with Ranpak's Cut'it! EVO height-reduction and box-sealing machine or similar systems, Print'it! can apply unique full-colour designs to packages without requiring additional manual handling, thereby maintaining the efficiency of the automation process.
This capability is particularly appealing to third-party logistics providers, e-commerce platforms, and fulfilment centres that aim to differentiate their packaging.
With the launch of Print'it!, Ranpak underscores its commitment to innovation in sustainable, paper-based packaging solutions.
Ranpak Automation global managing director Bryan Boatner said: 'The Print'it! solution unlocks new personalisation capabilities for automated packaging lines that are exciting for both operations and marketing.
'It's the icing on the cake of the improved total packaging solution that Ranpak Automation delivers for end-customers. And it's achievable while optimising efficiency for our clients, helping them consolidate their SKUs [stock-keeping units] and streamline their processes.'
Earlier this month, Ranpak teamed up with Rabot, a company specialising in vision AI technology to provide its customers with advanced insights.
"Ranpak unveils in-line printing for packaging automation" was originally created and published by Packaging Gateway, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Allsteel Announces Enhancements to Evo Chair for an Eco-Friendly, Refined Design
Evo Series Expands with Options for Increased Material and Color Expression and User Comfort Chicago, IL., June 02, 2025 (GLOBE NEWSWIRE) -- Workplace solutions leader Allsteel has expanded its best-selling Evo series with a more sustainable seating option, designed for everyone, everywhere. Evo's new enhancements allow the chair to meet the ever-changing demands of modern workspaces while pushing the boundaries of versatility, sustainability, and human-centered design. Now offering options for an eco-friendly Quilted Knit Back made from SEAQUAL® upcycled marine litter as well as carbon neutral models, the upgraded Evo collection not only enhances the overall chair's design but adds a layer of sustainability that align with Allsteel's core principles. Evo breaks ground with its new sustainable back. In collaboration with Camira Fabrics and their precision-crafted knits, Evo's quilted knit is produced with a zero-waste manufacturing process, fusing comfort with environmental consciousness. Meticulously fashioned with SEAQUAL® upcycled marine litter, the engineered knit is woven directly to size—eliminating scrap, glue, and sewing. This knit features a quilted infill structure with pillow-like channels that contour to the user's natural back shape. A loose, responsive yarn moves freely within each channel, allowing the surface to flex, expand, and shift in real time with every movement. The result: a back design that is both visually and tactilely soft—bringing human motion and material harmony together. Inspired by the hand-crafted nature of upholstery and the sleek performance of mesh, the Quilted Knit Back introduces a new material category that offers tactile comfort with sculpted performance. Evo's elevated aesthetics, intricate textures, dynamic patterns, and refined pillow-like design create a visually striking appearance. 'Allsteel is constantly updating its portfolio to ensure adherence to our commitment to sustainable, innovative, and functional design,' said Allsteel Director of Product Marketing, Aaron Snyder. 'Our expansion of Evo exemplifies this, providing designers and workplaces with a seating option to suit everyone's needs. With the new Quilted Knit Back and Evo carbon-neutral options, we're upholding our company's responsibility to design not only for the workplace, but also to provide quality solutions that are overall better for the environment.' Its minimalistic, quilted 'T' pattern backing highlights Evo's inherent lumbar support, providing ergonomic comfort without additional poly components, while an adhesive-free application preserves material integrity and allows for easy disassembly and recycling at the end of its lifecycle. This construction aligns with Allsteel's circular design intent. The Quilted Knit Back's responsive infill and dynamic channeling allow the chair to flex and adjust in real time, offering a comfort experience that supports the user's body throughout the day. Paired with Evo's additional features – including weight activated control for responsive tension, dual density foam that instantly supports a range of user types, and 4D Arms that supplement movement and posture variation – Evo offers a seating option that provides multiple levels of comfort and support in one place. In addition to its eco-friendly design, select Evo models are now certified as carbon neutral; Allsteel offsets each chair's carbon footprint using third-party Verified Carbon Standard Credits (VCS carbon offsets), which support the stewardship and management of U.S. based reforestation projects. The Evo collection also holds SCS Indoor Advantage™ Gold and BIFMA LEVEL® 3 certifications, reflecting Allsteel's broader commitment to responsible material choices, low emissions, and sustainable manufacturing. Evo's Carbon Neutral expansion reflects Allsteel's 'Designed to Do Better' commitment by merging sustainability, innovation, and ergonomic comfort. The Evo expansion introduces painted aluminum as a new finish option—bringing even greater design flexibility to one of Allsteel's most versatile seating solutions. With 40 curated paint choices available for the fixed aluminum arms and bases, Evo can now be tailored to complement any aesthetic, material palette, or workspace vision – equipping the user with the flexibility of expression. For more information on the Evo chair and its expanded features, visit the Allsteel website here: CONTACT: Majesty Henry Allsteel 7086546686 majesty@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
30-05-2025
- Business Upturn
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) — In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. Small Particle Detection : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. : Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data. Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.' The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth. For more information, please visit About Cytek Biosciences, Inc. Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080 [email protected]
Yahoo
29-05-2025
- Yahoo
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
Improved Sample Throughput, Automation Capabilities and Updated Hardware Design Cytek Aurora™ Evo FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system. First launched in 2017 to address the limitations of existing flow cytometry technologies, Cytek's Full Spectrum Profiling™ (FSP®) systems have become the spectral technology of choice for researchers worldwide, with over 2,600 peer-reviewed publications citing its use – more than any other spectral flow cytometer. Building on this groundbreaking success, the new Cytek Aurora Evo system has been reengineered to carry forward the proven reliability and reproducibility of the Cytek Aurora system, while introducing high-throughput and automation capabilities to meet the demands of modern research. The Cytek Aurora Evo system utilizes Cytek's FSP technology, continuing to provide the field-tested capability to run large multicolor experiments without compromising data quality, as well as an unparalleled level of assay flexibility. The ability to resolve both small particles and large cells on a single instrument allows scientists to tackle a wider range of applications with confidence. The newly added capabilities of improved sample throughput, automated instrument maintenance, and data harmonization were all added to empower researchers to accelerate discoveries with greater speed and confidence. With increasing demand for high-performance, flexible, and efficient cell analysis tools, the new Cytek Aurora Evo flow cytometer is well-positioned to meet the evolving needs of researchers and further drive the adoption of spectral flow cytometry. Key features and benefits of the new system include: Instrument Standardization: Harmonized instruments allow for consistent, accurate and reproducible biological data across systems, labs and time. High-Resolution and Throughput: A unique optical and electronics design enables excellent sensitivity and resolution across flow rates, from low (15 µL/min) to max (200 µL/min). Samples can now be acquired 2x faster than before. Small Particle Detection: Previously available as an optional upgrade on the Cytek Aurora system, this capability is now built into the new Cytek Aurora Evo flow cytometer, enabling researchers to detect and resolve extracellular vesicles, viruses, bacteria and other nanoparticles. Automation Capabilities: Minimize instrument maintenance and maximize efficiency. An integrated plate loader supports multiple carrier types, offering flexible user modes for both low carryover and high-throughput needs. Automated startup and shutdown further streamline workflows, reducing downtime while ensuring high-quality, high-resolution data. Recognized as a pioneer in spectral flow cytometry, Cytek's distinctive approach is renowned for its profound influence on advancing the understanding of cell biology, immunology, oncology and targeted therapeutic methodologies. 'Cytek's Aurora and Northern Lights™ systems have helped revolutionize immunology research and single-cell analysis,' said Ming Yan, Ph.D., CTO of Cytek Biosciences. 'Over the years, we have continuously pushed the boundaries of what's possible in spectral flow cytometry. With this latest launch of the Cytek Aurora Evo system, we've integrated these advancements into a powerful, high-throughput workhorse that delivers an unmatched combination of performance, reliability, efficiency and ease of use – enabling more scientists to leverage the full potential of spectral flow cytometry.' The Cytek Aurora Evo system will make its public debut at CYTO 2025, with demonstrations taking place in Cytek's booth. For more information, please visit About Cytek Biosciences, Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis, Guava and Muse are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website ( LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek's business strategies, product plans and expectations, and market opportunities. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled 'Risk Factors' set forth in Cytek's Quarterly Report on Form 10-Q filed on May 8, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek's as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@ Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@ A photo accompanying this announcement is available at in to access your portfolio
